One-Pot Processing And The Benefits For Granulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

One-Pot Processing And The Benefits For Granulation


Pharmaceutical Technology Europe
Volume 23, Issue 3


Griet Van Vaerenbergh
One-pot processing is a term that includes any technology that combines different unit operations of a pharmaceutical production process into one machine. In most cases, however, a onepot processor refers to a high shear mixer–granulator that is also equipped with drying technologies. Thus, onepot processing is the production of pharmaceutical granules using a wet granulation process in which dry mixing, liquid addition, wet granulation, drying and sizing of the granules is all performed in one machine.

The benefits of this type of processing are:

  • By integrating granulating and drying capabilities into a single unit, capital investment in equipment and GMP floor space is lower compared with other alternatives.
  • The number of material handling steps is decreased. Consequently, the total processing time is shorter while maintaining a high yield and keeping production support to a minimum. At the same time, the number of required operators is also reduced.
  • Environmental variables, such as humidity, are eliminated from the manufacturing process, which may offer advantages for processing moisture-sensitive formulations.
  • Requirements for solvent recovery systems are lower compared with fluid bed dryers.
  • Reaching a high level of containment is easy by application of the correct measures at in and outlet valves.
  • A single pot can be changed over in less than 2 hours, which makes it a very attractive technology if a large number of different products demanding a high number of product changeovers has to be produced.

Single pot processing has always been a niche technology in the pharma industry, but interest has increased in recent years because of the advantages it offers for producing highly potent compounds, such as oncology medicines and hormones. The concept of a onepot processor in itself already ensures contained processing. Because all unit operations are combined into one machine, the product is completely contained from charging the raw materials up to discharging the dry granulate ready for compression. No product transfers during the process are required, thus drastically reducing the exposure risk. By applying the correct containment measures to loading and discharge valves, a high level of containment is easily achieved.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here